Hybrid Quinazoline 1,3,5‐Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study,ChemMedChem

当前位置： X-MOL 学术 › ChemMedChem › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Hybrid Quinazoline 1,3,5‐Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study
ChemMedChem ( IF 3.6 ) Pub Date : 2020-11-05 , DOI: 10.1002/cmdc.202000646
Prateek Pathak ₁ , Hrvoje Rimac _{1,

2} , Maria Grishina ₁ , Amita Verma ₃ , Vladimir Potemkin ₁

Affiliation

We report a series of hybrid quinazoline‐1,3,5‐triazine derivatives as EGFR inhibitors, which were synthesised and tested by using a variety of in vitro, in silico, and in vivo techniques. The derivatives were found to be active against different cancer cell lines and nontoxic against normal ones, with compounds 7 c, 7 d, 7 e, and 7 j being the most potent ones. The derivatives were also evaluated for angiogenesis inhibition potency in chicken eggs, and molecular docking and dynamics simulation studies were carried out to elucidate the fundamental substituent groups essential for their bioactivity. Additionally, a SAR study of the derivatives was performed for future compound optimisation. These studies suggested that the derivatives have a high affinity towards EGFR with favourable pharmacological properties. The most active compound (7 e) was further evaluated for in vivo anticancer activity against DMBA‐induced tumours in female Sprague‐Dawley rats as well as its effects on plasma antioxidant status, biotransformation enzymes, and lipid profile. The study suggested that 7 e has lead properties against breast cancer and can serve as a starting compound for further development of anti‐EGFR compounds.

中文翻译：

杂种喹唑啉 1,3,5-三嗪作为具有抗癌活性的表皮生长因子受体 (EGFR) 抑制剂：设计、合成和计算研究

我们报告了一系列作为 EGFR 抑制剂的混合喹唑啉-1,3,5-三嗪衍生物，它们是通过使用各种体外、计算机和体内技术合成和测试的。发现这些衍生物对不同的癌细胞系具有活性，对正常细胞系无毒，化合物7 c、7 d、7 e和7 j是最有力的。还评估了这些衍生物在鸡蛋中的血管生成抑制效力，并进行了分子对接和动力学模拟研究，以阐明对其生物活性必不可少的基本取代基。此外，还对衍生物进行了 SAR 研究，以用于未来的化合物优化。这些研究表明，这些衍生物对 EGFR 具有高亲和力，具有良好的药理特性。进一步评估了活性最强的化合物 ( 7e )对雌性 Sprague-Dawley 大鼠中 DMBA 诱导的肿瘤的体内抗癌活性及其对血浆抗氧化状态、生物转化酶和脂质谱的影响。该研究表明，7 e 具有抗乳腺癌的先导特性，可作为进一步开发抗 EGFR 化合物的起始化合物。

更新日期：2020-11-05

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11